Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE-AQ PRESERVED vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate and inhibition of DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine synthesis and modulation of cytokine release.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
FDA-approved for acute lymphoblastic leukemia (ALL), meningeal leukemia, non-Hodgkin's lymphoma, mycosis fungoides, psoriatic arthritis, severe psoriasis, breast cancer, head and neck cancers, and rheumatoid arthritis. Off-label uses include ectopic pregnancy, inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, and lupus nephritis.
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
MEXATE-AQ PRESERVED (methotrexate) is administered intramuscularly, intravenously, or subcutaneously. For neoplastic diseases, typical adult doses range from 25-100 mg/m² weekly or 5-25 mg/m² every 6-12 hours for 2-6 doses. For rheumatoid arthritis, 7.5-20 mg once weekly. For psoriasis, 10-25 mg once weekly.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life is 3-10 hours for low-dose therapy; at high doses, half-life increases to 8-15 hours due to saturation of renal clearance. Clinical context: Prolonged half-life in renal impairment or third-space fluid accumulation.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Primarily metabolized hepatically to polyglutamated methotrexate (active form) via folylpolyglutamate synthetase; also undergoes oxidation via aldehyde oxidase. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily renal (80-90% unchanged via glomerular filtration and active tubular secretion), with approximately 5-10% eliminated via biliary/fecal excretion. Enterohepatic recirculation occurs.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 50-60% bound to albumin, with binding saturable at high concentrations.
47% bound to plasma proteins (primarily albumin)
Vd is 0.4-0.8 L/kg, indicating distribution into total body water. Higher Vd (1-2 L/kg) in high-dose therapy due to tissue binding and polyglutamation.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Oral: 30-90% (dose-dependent, saturable absorption; lower at high doses). IM/Sub Q: 100% (complete absorption). IV: 100%.
IV: 100% (only IV route); oral: not approved
Contraindicated if creatinine clearance (Cr Cl) <10 m L/min. For Cr Cl 10-30 m L/min: reduce dose by 50%. For Cr Cl 30-60 m L/min: reduce dose by 25%. For Cr Cl >60 m L/min: no adjustment needed. Monitor renal function closely; high methotrexate doses may require additional hydration and alkalinization.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Contraindicated in Child-Pugh class C. For Child-Pugh class B: reduce dose by 50%. For Child-Pugh class A: no dose adjustment. Avoid use in patients with significant liver disease or chronic hepatitis. Monitor liver enzymes.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
For acute lymphoblastic leukemia: induction doses of 3.3-5 mg/m² IV or IM, or higher doses per protocol (e.g., 100-1000 mg/m² IV). For juvenile idiopathic arthritis: 10-15 mg/m² once weekly (max 20-25 mg). Doses based on body surface area; adjust for renal function.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
Elderly patients may have reduced renal function; start at low end of dose range (e.g., 5-7.5 mg weekly for rheumatoid arthritis). Monitor Cr Cl, liver function, and blood counts. Increased risk of myelosuppression and hepatotoxicity. Avoid high-dose methotrexate unless renal function confirmed adequate.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
Methotrexate can cause severe toxicity including myelosuppression, hepatotoxicity, nephrotoxicity, pulmonary fibrosis, and severe enterocolitis. Accidental overdose has led to fatalities. It should only be prescribed by physicians experienced with antimetabolite therapy and familiar with its toxicities.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Monitor for bone marrow suppression, hepatotoxicity (liver function tests), renal impairment (serum creatinine), pulmonary toxicity (pneumonia-like symptoms), gastrointestinal toxicity, neurotoxicity (especially in high-dose regimens), and increased risk of infections. Avoid concomitant NSAIDs with high-dose methotrexate. Use with caution in patients with ascites, pleural effusions, or dehydration.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Absolute: hypersensitivity to methotrexate; severe hepatic impairment; severe renal impairment (Cr Cl < 30 m L/min); severe bone marrow suppression; active infection; alcohol use disorder; pregnancy (Category X); breastfeeding. Relative: peptic ulcer disease; ulcerative colitis; obesity; diabetes.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Avoid folic acid supplements unless prescribed by your doctor for toxicity management. Caffeine may decrease methotrexate efficacy; limit intake. No specific food restrictions other than maintaining adequate hydration. Avoid grapefruit juice as it may alter methotrexate metabolism.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Category X. First trimester: high risk of miscarriage, CNS and skeletal malformations. Second/third trimester: growth restriction, developmental delay.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Contraindicated. Excreted in breast milk; M/P ratio unknown. Potential for infant toxicity.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
Increased clearance in pregnancy may require dose escalation; however, contraindicated in pregnancy.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
MEXATE-AQ PRESERVED (methotrexate) is a folate analog antimetabolite. Always verify dosing route: intrathecal use requires preservative-free formulation. Ensure adequate hydration and urine alkalinization (target urine p H >7.0) to prevent methotrexate precipitation in renal tubules. Monitor CBC, LFTs, and creatinine before each dose. Leucovorin rescue is mandatory for high-dose regimens; start 24 hours after methotrexate infusion and continue until methotrexate level <0.1 µmol/L. Avoid concomitant NSAIDs and sulfonamides methotrexate toxicity.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Take methotrexate exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol completely due to increased risk of liver damage.,Drink plenty of fluids (at least 2-3 liters per day) to prevent kidney damage.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, mouth ulcers, cough, or shortness of breath immediately.,Use effective contraception during treatment and for at least 3 months after stopping (men and women).,Do not take NSAIDs (e.g., ibuprofen, naproxen) without your doctor's approval; they can increase methotrexate toxicity.,Avoid live vaccines while on treatment.,Store at room temperature, protect from light, and do not freeze.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE-AQ PRESERVED vs CLOFARABINE, answered by our medical review team.
MEXATE-AQ PRESERVED is a Antineoplastic Agent that works by Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate and inhibition of DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine synthesis and modulation of cytokine release.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE-AQ PRESERVED and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE-AQ PRESERVED is: MEXATE-AQ PRESERVED (methotrexate) is administered intramuscularly, intravenously, or subcutaneously. For neoplastic diseases, typical adult doses range from 25-100 mg/m² weekly or 5-25 mg/m² every 6-12 hours for 2-6 doses. For rheumatoid arthritis, 7.5-20 mg once weekly. For psoriasis, 10-25 mg once weekly.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE-AQ PRESERVED and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE-AQ PRESERVED is classified as Category C. Category X. First trimester: high risk of miscarriage, CNS and skeletal malformations. Second/third trimester: growth restriction, developmental delay.. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.